National Institutes of Health (NIH) division the National Institute of Allergy and Infectious Diseases (NIAID) has initiated a Phase I clinical trial of vaccine AGS-v to prevent a range of mosquito-transmitted diseases such as the Zika virus, malaria, West Nile fever and dengue fever. 

Developed by UK-based pharmaceutical firm SEEK, AGS-v is an investigational vaccine designed to prevent the disease, as well as block the ability of mosquitoes to transmit such infections.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The vaccine is developed to trigger an immune response to mosquito saliva, instead of targeting a specific virus or parasite carried by mosquitoes.

It consists of four synthetic proteins from mosquito salivary glands designed to produce antibodies and generate a modified allergic response to prevent infection.

"The vaccine is developed to trigger an immune response to mosquito saliva, instead of targeting a specific virus or parasite carried by mosquitoes."

The randomised Phase I trial is expected to enrol approximately 60 healthy adults between 18 and 50 years of age in three vaccine regimens, and will evaluate the safety and ability of the test vaccine to generate an immune response.

See Also:

Approximately 21 days after the vaccination schedule completion, the participants will undergo a controlled exposure to biting mosquitoes without any viruses or parasites.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Analysis of the blood samples and a physical examination will be carried out after the vaccinations and the exposure in order to measure levels of antibodies induced by vaccination and any changes caused after the exposure.

Investigators will also assess the mosquitoes after the feeding for changes in their behaviour or lifecycle that would help them determine the ability of the vaccine to hinder disease transmission.

The trial is being conducted at the NIH Clinical Center in Bethesda, Maryland, and is expected to be completed by next year.